Hyperimmune immunoglobulin does not improve outcomes in patients hospitalized with COVID-19
1. Hyperimmune intravenous immunoglobulin (hIVIG) did not increase odds of better outcomes in patients with COVID-19 compared to placebo. 2. ...
Tag: convalescent plasma
Convalescent plasma is not effective at improving clinical outcomes or reducing mortality of COVID-19 patients not on mechanical ventilation
1. This meta-analysis found that treatment with COVID-19 convalescent plasma (CCP), compared to control group treatment, did not improve clinical ...
#VisualAbstract: The use of COVID-19 convalescent plasma not beneficial to patients hospitalized with COVID-19
1. The use of COVID-19 convalescent plasma did not benefit patients hospitalized with COVID-19, assessed using the World Health Organization ...
The use of COVID-19 convalescent plasma not beneficial to patients hospitalized with COVID-19
1. The use of COVID-19 convalescent plasma did not benefit patients hospitalized with COVID-19, assessed using the World Health Organization ...
High-titre convalescent plasma therapy not effective against severe COVID-19 pneumonia
1. Amongst patients with severe COVID-19 pneumonia, there was no difference in 30-day all-cause mortality, ventilation or cure in patients ...
Convalescent plasma does not improve survival in patients hospitalized with COVID-19
1. A similar proportion of patients died within 28 days of randomization in both groups (high-titre convalescent plasma vs. usual ...
#VisualAbstract: Convalescent plasma transfusion provides mortality benefit in early COVID-19 disease stage
1. Transfusion of high-titer convalescent antibody plasma was associated with a lower risk of death from coronavirus disease 2019 (COVID-19), ...
Convalescent plasma transfusion provides mortality benefit in early COVID-19 disease stage
1. Transfusion of high-titer convalescent antibody plasma was associated with a lower risk of death from coronavirus disease 2019 (COVID-19), ...
Progression of COVID-19 reduced after high-titer convalescent plasma administration
1. Majority of the patients that received high-titer convalescent plasma within 72 hours of mild symptom onset were shown to ...
Early high-titer plasma therapy may reduce progression of COVID-19 in older patients
1. Patients aged 65 years or greater who received convalescent plasma within 72 hours of symptom onset were less likely ...